France · Delayed Price · Currency is EUR MaaT Pharma Earnings Call Transcripts
Fiscal Year 2025
-
An exclusive partnership with Clinigen will commercialize Xervyteg across Europe, supported by a €10.5M upfront payment, milestones, and royalties. EMA review is underway, early access demand is rising, and the deal extends the cash runway to early 2026, setting a benchmark for future growth.
-
The ARES phase 3 trial of MaaT013 in severe, refractory acute GVHD demonstrated a 62% GI response rate at day 28 and a 54% one-year survival, far surpassing historical outcomes. Regulatory submission in Europe is imminent, with commercialization and expansion plans supported by strong safety, robust real-world data, and a EUR 750 million market opportunity.
Fiscal Year 2024
-
KOLs highlighted the strong efficacy and safety of MaaT013 in severe, refractory GVHD, especially for ruxolitinib-refractory patients, with sustained responses and improved survival. Upcoming phase 3 results in early 2025 are expected to be pivotal for regulatory approval and market expansion.